Loading
A phase 1/2 trial of Vepdegestrant and Ribociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) is a phase 1/2 interventional study registered as NCT05573555 by Pfizer, with 20 participants enrolled, started 2023-03-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: ARV-471 and Ribociclib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, UCSF Helen Diller Family Comprehensive Cancer Center, Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/